All In Biotech

Drug Trial Radar · NCT00160121

Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease

A Phase IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenol Compared to Existing Therapy in Adults With End Stage Renal Disease Treated for Hyperphosphatemia

Last checked: Nov 20, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,500

Actual

Start

Jan 10, 2005

Primary completion

Dec 13, 2005

Study completion Dec 13, 2005

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test how well lanthanum carbonate reduces the pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal disease and to determine the patient and physician's satisfaction.

Conditions

  • Kidney Failure, Chronic

Interventions

  • Lanthanum carbonateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-dialysis serum phosphorus levels at 12 weeksTime frame: Week 12
  2. Patient satisfaction questionnaire at 12 weeksTime frame: Week 12
  3. Physician satisfaction questionnaire at 12 weeksTime frame: Week 12
  4. Patient preference questionnaire at 12 weeksTime frame: Week 12
  5. Physician preference questionnaire at 12 weeksTime frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.